Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 10-acetoxy-10,11-dihydro-5h-dibenz(b,f)azepine-5-carboxamide
2. Aptiom
3. Bia 2-093
4. Bia-2-093
5. Zebinix
1. 236395-14-5
2. Bia 2-093
3. Zebinix
4. Exalief
5. Aptiom
6. Stedesa
7. Erelib
8. Pazzul
9. Bia-2-093
10. Eslicarbazepine (acetate)
11. (s)-5-carbamoyl-10,11-dihydro-5h-dibenzo[b,f]azepin-10-yl Acetate
12. Sep-0002093
13. Eslicarbazepine Acetate [usan]
14. Bea68zvb2k
15. Chembl87992
16. Sep - 0002093
17. Chebi:87016
18. [(5s)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] Acetate
19. Bia-2093
20. Exelief
21. (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide
22. S-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide
23. Eslicarbazepine Acetate (usan)
24. (10s)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide
25. (10s)-5-carbamoyl-10,11-dihydro-5h-dibenzo[b,f]azepin-10-yl Acetate
26. (s)-10-acetoxy- 10,11-dihydro- 5h-dibenz[b,f]azepine- 5-carboxamide
27. 5h-dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10s)-
28. Sep 0002093
29. Unii-bea68zvb2k
30. (10s)-5-carbamoyl-10,11-dihydro-5h-dibenzo(b,f)azepin-10-yl Acetate
31. 5h-dibenz(b,f)azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10s)-
32. Bia 2093
33. Zebinix (tn)
34. Aptiom (tn)
35. Eslicarbazepine-acetate
36. Eslicarbazapine Acetate
37. Schembl250594
38. Zinc7295
39. Dtxsid90178308
40. Hms3263m06
41. Hms3885n14
42. Hy-b0703
43. Eslicarbazepine Acetate [mi]
44. Tox21_501102
45. Bdbm50240669
46. Mfcd06798333
47. S4657
48. Akos005145781
49. Ccg-222406
50. Db09119
51. Eslicarbazepine Acetate [mart.]
52. Eslicarbazepine Acetate [vandf]
53. Lp01102
54. Sdccgsbi-0633789.p001
55. Eslicarbazepine Acetate [who-dd]
56. Ncgc00165752-01
57. Ncgc00165752-02
58. Ncgc00165752-04
59. Ncgc00165752-06
60. Ncgc00261787-01
61. Ac-31734
62. As-14058
63. Eslicarbazepine Acetate [ema Epar]
64. E1046
65. Eslicarbazepine Acetate [orange Book]
66. Bia 2-093, >=98% (hplc), Solid
67. D09612
68. H11471
69. Ar-270/43507894
70. Q410273
71. J-015175
72. (s)-10-acetoxy-10,11-dihydro-5hdibenz( B,f)azepine-5-carboxamide
73. 10s)-5-carbamoyl-10,11-dihydro-5h-dibenzo[b,f]azepin-10-yl Acetate
74. 5-(aminocarbonyl)-10,11-dihydro-5h-dibenzo[b,f]azepin-10-yl Acetate
75. 5h-dibenz9b,f)azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10s)-
76. Acetic Acid (s)-5-carbamoyl-10,11-dihydro-5h-dibenzo[b,f]azepin-10-yl Ester
77. Acetic Acid 5-carbamoyl-10,11-dihydro-5h-dibenzo[b,f]azepin-10(s)-yl Ester
| Molecular Weight | 296.32 g/mol |
|---|---|
| Molecular Formula | C17H16N2O3 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 296.11609238 g/mol |
| Monoisotopic Mass | 296.11609238 g/mol |
| Topological Polar Surface Area | 72.6 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 440 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Aptiom |
| PubMed Health | Eslicarbazepine (By mouth) |
| Drug Classes | Anticonvulsant, Central Nervous System Agent |
| Drug Label | The chemical name of APTIOM (eslicarbazepine acetate) is (S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. APTIOM is a dibenz[b,f]azepine-5-carboxamide derivative. Its molecular formula is C17H16N2O3 and its molecular weight is 296.32... |
| Active Ingredient | Eslicarbazepine acetate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg; 600mg; 800mg; 400mg |
| Market Status | Prescription |
| Company | Sunovion Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Aptiom |
| PubMed Health | Eslicarbazepine (By mouth) |
| Drug Classes | Anticonvulsant, Central Nervous System Agent |
| Drug Label | The chemical name of APTIOM (eslicarbazepine acetate) is (S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. APTIOM is a dibenz[b,f]azepine-5-carboxamide derivative. Its molecular formula is C17H16N2O3 and its molecular weight is 296.32... |
| Active Ingredient | Eslicarbazepine acetate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg; 600mg; 800mg; 400mg |
| Market Status | Prescription |
| Company | Sunovion Pharms |
Eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients.
FDA Label
Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.
Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
Treatment of epilepsy with partial-onset seizures
Eslicarbazepine acetate is associated with a dose- and concentration-dependant increase in heart rate and prolongation of PR interval.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
N03AF04
N03AF04
Absorption
Eslicarbazepine active metabolite has a high bioavailability and reaches peak serum concentration 1-4 hours after a given dose. Eslicarbazepine acetate absorption is not affected by food.
Route of Elimination
Eslicarbazepine acetate and its metabolites are eliminated primarily via renal excretion. Eslicarbazepine active metabolite is excreted two-thirds in the unchanged form and one-third as a glucuronide conjugate. This accounts for around 90% of total metabolites excreted, with the remaining 10% being minor metabolites. Renal tubular reabsorption is expected to occur with eslicarbazepine.
Volume of Distribution
The apparent volume of distribution of eslicarbazepine is 61.3 L for a body weight of 70 kg based on population PK analysis.
Clearance
Renal clearance of eslicarbazepine was found to be approximately 20 mL/min in healthy subjects with normal renal function.
Eslicarbazepine acetate is rapidly and extensively metabolized to its major active metabolite, eslicarbazepine, via hydrolytic first-pass metabolism. Eslicarbazepine corresponds to about 92% of systemic exposure. Minor active metabolites (R)-licarbazepine and oxcarbazepine consist of <5% of systemic exposure. Active metabolites are then metabolized to inactive glucuronides that correspond to about 3% of systemic exposure. Eslicarbazepine had a moderate inhibitory effect on CYP2C19 and a mild activation of UGT1A1-mediated glucuronidation when studied in human hepatic microsomes. It has been shown to induce CYP3A4 enzymes in vivo.
The apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.
Eslicarbazepine acetate is converted to the active metabolite eslicarbazepine which carries out its anticonvulsant activity. The exact mechanism of action is unknown, but it is thought to involve the inhibition of voltage-gated sodium channels. In in vitro electrophysiological studies, eslicarbazepine was shown to inhibit repeated neuronal firing by stabilizing the inactivated state of voltage-gated sodium channels and preventing their return to the activated state. In vitro studies also showed eslicarbazepine inhibiting T-type calcium channels, which likely also has a role in anticonvulsant activity.
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38309
Submission : 2023-04-25
Status : Active
Type : II
Date of Issue : 2025-08-05
Valid Till : 2028-06-25
Written Confirmation Number : WC-0054
Address of the Firm :
Registrant Name : Husid Co., Ltd.
Registration Date : 2025-06-24
Registration Number : Su928-1-ND
Manufacturer Name : Ami Lifesciences Private Limited
Manufacturer Address : Block No. 82/B, ECP Road, At & Post: Karakhadi-391450, Taluka: Padra, District: Vadodara, Gujarat, India
| Available Reg Filing : ASMF, MX |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-07-05
Pay. Date : 2017-06-19
DMF Number : 31758
Submission : 2017-05-31
Status : Active
Type : II
Date of Issue : 2025-07-15
Valid Till : 2028-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-933
Start Marketing Date : 2017-05-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-07-27
Pay. Date : 2017-06-09
DMF Number : 31791
Submission : 2017-06-05
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39312
Submission : 2023-12-28
Status : Active
Type : II
NDC Package Code : 52076-6269
Start Marketing Date : 2021-02-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-05-16
Pay. Date : 2017-04-12
DMF Number : 31500
Submission : 2017-04-03
Status : Active
Type : II
Date of Issue : 2025-08-05
Valid Till : 2028-06-16
Written Confirmation Number : WC-0049
Address of the Firm :
NDC Package Code : 83786-010
Start Marketing Date : 2025-03-05
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2025-10-22
Pay. Date : 2025-09-25
DMF Number : 42435
Submission : 2025-09-19
Status : Active
Type : II
NDC Package Code : 51508-210
Start Marketing Date : 2025-06-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32721
Submission : 2018-04-30
Status : Active
Type : II
Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm :
NDC Package Code : 69766-051
Start Marketing Date : 2018-04-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
About the Company : MINAKEM is a cGMP custom manufacturer specializing in small molecule APIs, HPAPIs, and steroids. Its highly skilled R&D teams, supported by strong analytical and regulatory service...
About the Company : Ami Lifesciences, established in 2006, is a rapidly growing API manufacturing company in India with strong capabilities in cardiovascular, anti-diabetic, CNS, and respiratory thera...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Minakem Montreal is developing and manufacturing small molecules APIs and advanced intermediates, including corticosteroids. Following efficient processes and methodologies, our em...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers cost-effective APIs with speed, supported by a skilled team. As the first Southeast Asian company to receive FDA approv...
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...

About the Company : CTX is one of the youngest and fastest-growing Indian API and Intermediate manufacturing companies doing business in over 70 countries. In these five years, all my thoughts and act...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
18
PharmaCompass offers a list of Eslicarbazepine Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Eslicarbazepine Acetate manufacturer or Eslicarbazepine Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eslicarbazepine Acetate manufacturer or Eslicarbazepine Acetate supplier.
A Zebinix (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zebinix (TN), including repackagers and relabelers. The FDA regulates Zebinix (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zebinix (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Zebinix (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Zebinix (TN) supplier is an individual or a company that provides Zebinix (TN) active pharmaceutical ingredient (API) or Zebinix (TN) finished formulations upon request. The Zebinix (TN) suppliers may include Zebinix (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Zebinix (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Zebinix (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Zebinix (TN) active pharmaceutical ingredient (API) in detail. Different forms of Zebinix (TN) DMFs exist exist since differing nations have different regulations, such as Zebinix (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Zebinix (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Zebinix (TN) USDMF includes data on Zebinix (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zebinix (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Zebinix (TN) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Zebinix (TN) Drug Master File in Korea (Zebinix (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zebinix (TN). The MFDS reviews the Zebinix (TN) KDMF as part of the drug registration process and uses the information provided in the Zebinix (TN) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Zebinix (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zebinix (TN) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Zebinix (TN) suppliers with KDMF on PharmaCompass.
A Zebinix (TN) written confirmation (Zebinix (TN) WC) is an official document issued by a regulatory agency to a Zebinix (TN) manufacturer, verifying that the manufacturing facility of a Zebinix (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Zebinix (TN) APIs or Zebinix (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Zebinix (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Zebinix (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zebinix (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Zebinix (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Zebinix (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Zebinix (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zebinix (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Zebinix (TN) suppliers with NDC on PharmaCompass.
Zebinix (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zebinix (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Zebinix (TN) GMP manufacturer or Zebinix (TN) GMP API supplier for your needs.
A Zebinix (TN) CoA (Certificate of Analysis) is a formal document that attests to Zebinix (TN)'s compliance with Zebinix (TN) specifications and serves as a tool for batch-level quality control.
Zebinix (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Zebinix (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zebinix (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Zebinix (TN) EP), Zebinix (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zebinix (TN) USP).